The Tarrytown, NY-based Progenics Pharmaceuticals outlined plans to cut 38 staffers--about a quarter of its staff--and narrow its discovery focus to oncology as it pares back the burn rate. The biotech also plans to close its cGMP manufacturing facility. CEO Mark Baker, who joined the troubled biotech earlier this year, billed the moves as a strategic effort aimed at making the company leaner,...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Progenics slashes staff, closes facility and narrows focus in latest restructuring
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account